Rosacea - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Rosacea - Pipeline Review, H2 2016

Rosacea - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Rosacea - Pipeline Review, H2 2016
Published Oct 26, 2016
72 pages — Published Oct 26, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rosacea Pipeline Review, H2 2016, provides an overview of the Rosacea (Dermatology) pipeline landscape.

Rosacea is a chronic and potentially life-disruptive disorder primarily of the facial skin, often characterized by flare-ups and remissions. Symptoms include frequent redness of the face, or flushing, small, red lines under the skin, a swollen nose and thick skin, usually on the forehead, chin, and cheeks. The predisposing factors include age and family history of rosacea. Treatment includes antibiotics and acne drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rosacea Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Rosacea (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rosacea (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Rosacea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 2, 7, 3, 1 and 3 respectively for Rosacea.

Rosacea (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Rosacea (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Rosacea (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Rosacea (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Rosacea (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Rosacea (Dermatology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D stra

  
Source:
Document ID
GMDHC8586IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables51
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
Rosacea Overview81
Therapeutics Development91
  Pipeline Products for Rosacea Overview91
Rosacea Therapeutics under Development by Companies101
Rosacea Pipeline Products Glance113
  Late Stage Products111
  Clinical Stage Products121
  Early Stage Products131
Rosacea Products under Development by Companies141
Rosacea Companies Involved in Therapeutics Development1510
  Allergan Plc151
  Amorepacific Corporation161
  Cell Medica Limited171
  Cutanea Life Sciences Inc181
  Foamix Pharmaceuticals Ltd.191
  Hovione FarmaCiencia SA201
  Merz Pharma GmbH &Co. KgaA211
  Promius Pharma, LLC221
  Sol-Gel Technologies Ltd.231
  TWi Pharmaceuticals, Inc.241
Rosacea Therapeutics Assessment259
  Assessment by Monotherapy Products251
  Assessment by Target262
  Assessment by Mechanism of Action282
  Assessment by Route of Administration302
  Assessment by Molecule Type322
Drug Profiles3425
  AC-701 Drug Profile341
  ACUD-1 Drug Profile351
  B-244 Drug Profile361
  benzoyl peroxide Drug Profile371
  brolucizumab Drug Profile382
  CLS-005 Drug Profile401
  DFD-29 Drug Profile411
  DMT-200 Drug Profile422
  DMT-210 Drug Profile441
  DMT-220 Drug Profile451
  FMX-103 Drug Profile462
  incobotulinumtoxin A Drug Profile483
  itraconazole Drug Profile511
  minocycline Drug Profile521
  omiganan pentahydrochloride Drug Profile532
  oxymetazoline hydrochloride Drug Profile552
  PAC-14028 Drug Profile572
Rosacea Dormant Projects592
Rosacea Discontinued Products611
Rosacea Product Development Milestones629
  Featured News &Press Releases621
    Sep 28, 2016: Dermata Therapeutics, LLC Announces Positive Top-line Results from their Phase 1 Pharmacokinetic Study of DMT210 in Acne Rosacea Patients621
    Sep 12, 2016: Foamix Announces Positive Topline Results from Phase 2 Trial Evaluating FMX-103 Topical Minocycline Foam for Moderate-to-Severe Papulopustular Rosacea621
    Sep 09, 2016: Foamix to Announce Topline Results in Phase 2 Clinical Trial of FMX-103 Minocycline Topical Foam for Moderate-to-Severe Papulopustular Rosacea631
    May 24, 2016: Allergan Announces FDA Acceptance of NDA Filing for Oxymetazoline HCI Cream 1.0%631
    May 19, 2016: Galderma Laboratories Announces Availability of New Mirvaso (brimonidine) Topical Gel, 0.33% Pump Dispenser for the Treatment of the Persistent Facial Redness of Rosacea641
    May 16, 2016: Dermata Therapeutics Announces Initiation of Phase 1 Pharmacokinetic Study641
    May 03, 2016: Foamix Announces Completion of Enrollment in Phase 2 Clinical Trial of Minocycline Foam (FMX103) for Treatment of Papulopustular Rosacea651
    Oct 20, 2015: Foamix Announces Enrollment of First Patient in Phase 2 Clinical Trial of FMX103 in Papulopustular Rosacea651
    Apr 17, 2014: Treatment for Facial Redness Associated With Rosacea Now Available in the UK661
    Feb 26, 2014: mirvaso the first and only treatment targeting the facial redness of rosacea approved by the european commission661
    Jan 29, 2014: Galderma Announces the Publication of Positive Results of the Long-Term Study of Mirvaso Gel for Treatment of Persistent Erythema of Rosacea671
    Dec 20, 2013: Galderma Receives CHMP Positive Opinion For Mirvaso681
    Sep 27, 2013: Galderma Announces Availability of Mirvaso (brimonidine) Topical Gel, 0.33%681
    Aug 26, 2013: Galderma Receives FDA Approval of Mirvaso691
    Jul 08, 2013: Signum Dermalogix Investigational New Drug Application Cleared by FDA: SIG990 a Potential Treatment for Rosacea701
Appendix712
  Methodology711
  Coverage711
  Secondary Research711
  Primary Research711
  Expert Panel Validation711
  Contact Us711
  Disclaimer721

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Rosacea - Pipeline Review, H2 2016" Oct 26, 2016. Alacra Store. May 04, 2025. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Rosacea-Pipeline-Review-H2-2016-2088-16701>
  
APA:
Global Markets Direct - Market Research. (2016). Rosacea - Pipeline Review, H2 2016 Oct 26, 2016. New York, NY: Alacra Store. Retrieved May 04, 2025 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Rosacea-Pipeline-Review-H2-2016-2088-16701>
  
US$ 2,000.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.